IDT Biologika to Expand Vaccine Capacity and Workforce
IDT Biologika, GmbH (Dessau-Rosslau, Germany), a contract manufacturer of vaccines and biopharmaceuticals, will expand its viral vaccine production capacity with the addition of a new high-speed filling line and additional lyophilization capacity. The company also will add 80 employees to its workforce?an increase of approximately 11%?to meet growth in demand for its biologics production.
IDT Biologika, GmbH (Dessau-Rosslau, Germany), a contract manufacturer of vaccines and biopharmaceuticals, will expand its viral vaccine production capacity with the addition of a new high-speed filling line and additional lyophilization capacity. The company also will add 80 employees to its workforce—an increase of approximately 11%—to meet growth in demand for its biologics production.
IDT Biologika expects to expand its vaccine manufacturing facilities through the completion of its new high-speed viral vaccine line by mid-2013. This line will substantially expand fill-finish capacity and position the company for anticipated growth in demand for this service. The company’s existing vaccine facility features two contained manufacturing lines with segregated operations for preparation of cells, virus propagation, and virus purification.
The Solution Lies with SOLBIOTE™: Achieving Sustainability, a Growing Focus in Biopharma
October 28th 2024The nexus between biopharmaceuticals and sustainability is seemingly far apart, however, it is increasingly recognized as an inevitable challenge. It is encouraged to take a sustainable approach to reducing the environmental impact of the production and supply of medicines while improving people's health; delivering the well-being of people and the planet. Yosuke Shimojo (Technical Value Support Section Manager, Nagase Viita) will unveil how SOLBIOTE™, a portfolio of injectable-grade saccharide excipients, would be a key for the biopharmaceutical development and achieving sustainability for a better future of the industry.
